Contents

Issue 114 • January 2022

In association with

The challenges of multiple drugs safety reporting

Safety reporting for treatments involving multiple drugs must improve to protect patients from harmful drug-drug interactions

IN DEPTH

Pfizer and Takeda deals put a spotlight on value-based pricing

Comment

How has AI helped in combating the spread of Covid-19?

Briefing

Industry news

Pharma industry briefing

Covid-19 briefing

Comment

How has AI helped in tackling Covid-19?

What does Ireland’s tax hike mean for pharma?

Chinese review designations lag behind US and EU

The benefits of text mining for life sciences

In Depth

Narrow FDA vote on Merck’s molnupiravir bolsters outlook on mAbs

The challenges of multiple drugs safety reporting

Pfizer and Takeda deals put a spotlight on value-based pricing

3D printing in drug manufacturing: unlocking future possibilities

Can drug repurposing uncover better treatments for UTIs?

Lethal injection: can pharma kill the death penalty?

In Data

Data analytics jobs in clinical trials are on the rise

Middle-income countries’ healthcare markets will continue to grow

Industrial automation innovation in pharma rebounds

Markets and indices

Macro-economic data